Skip to main content
Premium Trial:

Request an Annual Quote

Pharmacopeia Announces New Promotions, Splits COO Position

NEW YORK, Feb 13 – Bioinformatics tool provider Pharmacopeia said Tuesday it had promoted Michael Stapleton to the position of chief operating officer for the company’s software division and Stephen Spearman to the position of chief operating officer for the company’s drug discovery business.

The Princeton, NJ-based company decided to create two COO positions for the different divisions following the resignation of Saiid Zarrabian in December.

“Given the current size and growth potential of our drug discovery and software businesses, we felt it was important to put experienced leaders at the helm of each business,” Joseph Mollica, Pharmacopeia's CEO, said in a statement.

Stapleton, who has been with Pharmacopeia for the last 10 years, most recently served as the executive vice president of software operations. The division makes software for molecular modeling and simulation, gene sequence analysis, cheminformatics, bioinformatics, knowledge management, and decision support.

Spearman has worked for Pharmacopeia since 1996 and was most recently executive vice president of discovery technologies. The company’s drug discovery business helps to optimize lead compounds for customers.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.